Abstract: The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.

Abstract: The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.

Abstract: The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KED) biocatalyst enzymes and methods of using the biocatalysts.

Abstract: Disclosed herein is a novel process for preparing Compound A free base, 5-((2,4-diaminopyrimidin-5-yl)oxy)-4-iso-propyl-2-methoxybenzenesulfonamide, and a citrate salt of Compound A with simplified chemistry and a high overall yield: Compound A. In one embodiment, the overall yield from the starting material 2-isopropylphenol to Compound A citrate salt is greater than 50%. In another embodiment, the overall yield is greater than 60%. Also disclosed herein are novel salts and solvates of Compound A.

Abstract: The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.

Abstract: The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.

Abstract: The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.

Abstract: The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.

Abstract: The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams. One use of the methods and intermediates described herein is in the production of macrolactam compounds able to inhibit HCV NS3 protease activity. HCV NS3 inhibitory compounds have therapeutic and research applications.

Abstract: This invention provides processes for the preparation of verubecestat (Compound of Formula (I)), a potent inhibitor of BACE-1 and BACE-2. In addition, the invention provides certain synthetic intermediates which are useful, among other things, for the preparation of the Compound of Formula (I).

Abstract: The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of 1-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.

Abstract: The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams. One use of the methods and intermediates described herein is in the production of macrolactam compounds able to inhibit HCV NS3 protease activity. HCV NS3 inhibitory compounds have therapeutic and research applications.

Abstract: Apparatus and method are disclosed for guiding a payload to a target location. The apparatus comprises a laser radiation source, a laser radiation reflecting arrangement for generating substantially spatially homogeneous reflected laser radiation, an activator for activating the radiation source to generate laser radiation and an electrical power source for powering the apparatus.

Abstract: There is disclosed a collar (100) which may be attached to a munition in order to control the trajectory of the munition. The collar (100) has a collar body (10); a surface (12) for capturing the projectile as it leaves the barrel; a sill (14) for supporting the surface (12) at the muzzle of the barrel; and a guidance means (20a, 20b, 21a, 21b) for altering the flow of air around the collar (100). The collar (100) supports itself at the muzzle and may attach to the projectile at the surface (12) to integrate with the projectile as the projectile is fired. The collar (100) is particularly suited for attachment to mortar rounds. Such a collar (100) gives a weapon operator the option of increasing the precision of a munition without having to carry a plurality of munition types.

Abstract: The present disclosure relates to a launch system for air vehicles. More specifically, the present disclosure relates to launching unmanned air vehicles (UAVs) that are unable to be launched by hand. The present disclosure provides a system for launching a winged vehicle, including: a projectile launching device; and a device for converting projectile momentum into acceleration of a winged vehicle.

Abstract: There is disclosed a collar (100) which may be attached to a munition in order to control the trajectory of the munition. The collar (100) has a collar body (10); a surface (12) for capturing the projectile as it leaves the barrel; a sill (14) for supporting the surface (12) at the muzzle of the barrel; and a guidance means (20a, 20b, 21a, 21b) for altering the flow of air around the collar (100). The collar (100) supports itself at the muzzle and may attach to the projectile at the surface (12) to integrate with the projectile as the projectile is fired. The collar (100) is particularly suited for attachment to mortar rounds. Such a collar (100) gives a weapon operator the option of increasing the precision of a munition without having to carry a plurality of munition types.

Abstract: The present invention is directed to processes for the preparation of 4-(3-methanesulfonyl-phenyl)-1-N-propylpiperidine (I) or a pharmaceutically acceptable salt thereof, which comprises: oxidizing a sulfide of the formula (II): with a catalytic oxidizing agent and an oxidant; to give a compound of the formula (III): followed by catalytic reduction of the compound of formula (III).

Abstract: The present disclosure relates to a launch system for air vehicles. More specifically, the present disclosure relates to launching unmanned air vehicles (UAVs) that are unable to be launched by hand. The present disclosure provides a system for launching a winged vehicle, including: a projectile launching device; and a device for converting projectile momentum into acceleration of a winged vehicle.

Abstract: The present invention is directed to processes for the preparation of 4-(sulfonylphenyl)-piperidines of the Formula (VI), and pharmaceutically acceptable salts thereof; which comprises oxidizing a sulfide of the Formula (VII) or Formula (VIII), to give a compound of the Formula (IX) or Formula (X) respectively, followed by catalic reduction of the compound of the Formula (IX) or dehydration of compound of formula (X) to give a compound of Formula (IX) followed by catalytic reduction of the compound formula (IX) to give the compound of the Formula (VI).

Abstract: The present invention is directed to processes for the preparation of 4-(3-methanesulfonyl-phenyl)-1-N-propylpiperidine (I) or a pharmaceutically acceptable salt thereof, which comprises: oxidizing a sulfide of the formula (II): with a catalytic oxidizing agent and an oxidant; to give a compound of the formula (III): followed by catalytic reduction of the compound of formula (III).